Please login to the form below

Not currently logged in

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

Roche and biotech company Prothena are set to advance their Parkinson’s disease candidate prasinezumab into a phase 2b efficacy trial following some promising results in an earlier trial.

The decision to advance clinical testing of prasinezumab is based on the results from the phase 2 PASADENA study. Although the study did not meet its primary objective of slowing the progression of motor and non-motor symptoms over the first year of treatment, the drug showed signs of efficacy on secondary and exploratory measures.

This included a reduction in disease progression in both prasinezumab arms compared to placebo. In addition, prasinezumab reduced decline motor function by 35% when compared to placebo after one year of treatment, using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III.

Patients treated with prasinezumab also demonstrated a significant delay in time to clinically meaningful worsening of motor progression versus placebo over one year.

"We are very encouraged by the results from PASADENA, demonstrating significant slowing of motor progression and improvements on imaging biomarkers consistent with disease modification, as this provides a rich dataset to directly inform and de-risk this next late-stage study," said Gene Kinney, president and chief executive officer of Prothena.

Prasinezumab is a monoclonal antibody designed to target alpha-synuclein, a protein found in neurons that can build up and spread from cell to cell. This results in the neuronal dysfunction and loss that ultimately leads to Parkinson’s disease.

In 2013, Roche and Prothena entered a collaboration agreement to develop and commercialise antibodies that target alpha-synuclein.

The deal saw Roche pay Prothena an upfront fee and near-term clinical milestones totalling $45m, with Prothena eligible to receive additional payments of up to $380m in the US.

The biotech company could also receive a further $175m worth of milestone payments for milestones reached outside the US, potentially taking the total payment to $600m.

Parkinson’s disease remains an area of high unmet medical need, despite a number of companies seeking to develop successful treatments for the neurodegenerative condition.

Currently, an estimated seven to ten million people are living with Parkinson’s across the globe, making it the second most common neurodegenerative condition after Alzheimer’s disease.

In August, Biogen signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for the deal.

Denali’s portfolio of small molecule LRRK2 inhibitors and transport vehicle technology platform has potential in a range of conditions, although its promise in Parkinson’s is the focus of the Biogen deal.

Article by
Lucy Parsons

21st October 2020

From: Research



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...